Clinical Study

Effects of a Multispecies Probiotic Mixture on Glycemic Control and Inflammatory Status in Women with Gestational Diabetes: A Randomized Controlled Clinical Trial

Sadegh Jafarnejad,1 Sadaf Saremi,2 Farzan Jafarnejad,3 and Arman Arab4

1Department of Clinical Nutrition, School of Nutritional Sciences and Dietetic, Tehran University of Medical Sciences, P.O. Box 14155-6117, Tehran, Iran
2Department of Public Health, Isfahan University of Medical Sciences, Isfahan, Iran
3Department of Health Information Management, Mazandaran University of Medical Sciences, Sari, Iran
4Department of Community Nutrition, School of Nutrition and Food Science, Isfahan University of Medical Sciences, Isfahan, Iran

Correspondence should be addressed to Sadegh Jafarnejad; sjafarnejad@razi.tums.ac.ir

Received 23 December 2015; Revised 30 April 2016; Accepted 10 May 2016

Academic Editor: Phillip B. Hylemon

Copyright © 2016 Sadegh Jafarnejad et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Objective. This trial aims to examine the effects of a Probiotic Mixture (VSL#3) on glycemic status and inflammatory markers, in women with GDM. Materials and Methods. Over a period of 8 weeks, 82 women with gestational diabetes were randomly assigned to either an intervention group (n = 41) which were given VSL#3 capsule or to a control group which were given placebo capsule (n = 41). Fasting plasma glucose, homeostatic model assessment of insulin resistance, glycosylated hemoglobin, high-sensitivity C-reactive protein, tumor necrosis factor-α, interleukin-6, interferon gamma, and interleukin-10 were measured before and after the intervention. Results. After 8 wk of supplementation FPG, HbA1c, HOMA-IR, and insulin levels remained unchanged in the probiotic and placebo groups. The comparison between the two groups showed no significant differences with FPG and HbA1c, but there were significant differences in insulin levels and HOMA-IR (16.6 ± 5.9; 3.7 ± 1.5, resp.). Unlike the levels of IFN-γ (19.21 ± 16.6), there was a significant decrease in levels of IL-6 (3.81 ± 0.7), TNF-α (3.10 ± 1.1), and hs-CRP (4927.4 ± 924.6). No significant increase was observed in IL-10 (3.11 ± 5.7) in the intervention group as compared with the control group. Conclusions. In women with GDM, supplementation with probiotics (VSL#3) may help to modulate some inflammatory markers and may have benefits on glycemic control.

1. Introduction

Every year up to 3 million US pregnant women are affected by gestational diabetes mellitus (GDM), diabetes mellitus during pregnancy, and it still has an increasing progress in pregnant women society [1]. GDM has unfavorable effects on both mother and the baby which could be categorized into short term and long term morbidities. Preeclampsia and delivery by cesarean section are the short term outcomes of GDM in mothers while hypoglycemia, excessive adiposity, shoulder dystocia, and macrosomia (baby’s birth weight > 8 pounds 13 ounces (4000 g)) are life threatening short term effects of GDM on newborns [2–5]. In long term, both mother and the baby might face with difficulties including increased risk of obesity, cardiovascular diseases, and metabolic disorders such as type 2 diabetes mellitus [4]. There are many papers which mention a 20% higher risk of type 2 diabetes mellitus within nine years after delivery so the women with GDM needs more intervention for reducing future risk of type 2 diabetes mellitus [6]. On the other hand, alteration in insulin
resistance in GDM predisposes women to inflammation that causes increased level of inflammatory markers like high sensitive C-reactive protein (hs-CRP) and fibrinogen [7].

Recently the role of the gut microbiota as a modulator of metabolic and inflammatory processes has been investigated. The gut microbiota is affected by many factors like antibiotic therapy [8], dietary patterns [9], weight loss [10], and pregnancy [4]. Intake of probiotics is a safe alternative for normalizing the gut microbiota. In 2002, the Joint FAO (Food and Agricultural Organization of the United Nations)/WHO (World Health Organization) Expert Consultation was held and the latest definition for probiotics was reported as “live microorganisms which, when administered in adequate amounts, confer health benefits on the host” [11]. The most important factors in efficacy of probiotics treatment in inflammatory and metabolic processes are genus and strains supplied in the probiotics. For example, some strains of lactic acid bacteria (LAB) could modulate inflammatory and hypersensitivity process [12]. VSL#3 which was used as an intervention in this trial contained eight strains of lactic acid bacteria (Streptococcus thermophilus, Bifidobacterium breve, Bifidobacterium longum, Bifidobacterium infantis, Lactobacillus acidophilus, Lactobacillus plantarum, Lactobacillus paracasei, and Lactobacillus delbrueckii subsp. Bulgaricus). This is the first time to investigate the effect of the specific probiotic on glycemic control and inflammatory status among the GDM subjects, although it has been previously used in other population groups [13–17]. So far the exact mechanisms of probiotics in alteration of the gut microbiota are not known [18].

In 2013, a prospective, double-blind randomized controlled trial was conducted on pregnant women which were recruited during 2 years. They received probiotics or a placebo capsule from 16 weeks of gestation until delivery. The results showed more than 50% change in gestational diabetes markers in pregnant women [4].

As previously mentioned, the VSL#3 probiotic has been used in other population groups to influence various blood parameters [13–17] but has not yet been studied in a GDM population. Therefore, a clinical trial was conducted in order to find the effects of this probiotics mixture on inflammatory markers and glycemic control in pregnant women with GDM.

2. Materials and Methods

On the basis of the sample size formula suggested for the similar randomized clinical trials [19] and considering types I and II error of 5% (α = 0.05) and 20% (β = 0.2; Power = 80%), respectively, and serum insulin level as a key variable, we reached the sample size of 44 women for each group. Of the 96 participants who were referred to Tuba endocrine clinic (Sari, Iran) and assessed for study eligibility, 89 participants met inclusion criteria. All 89 consecutive patients diagnosed with gestational diabetes in our department from May 2014 until October 2015 were asked to participate in our study. Among them, 82 agreed to participate and were randomly assigned by blocked randomization, at a ratio of 1:1, to take VSL#3 probiotic capsule (n = 41) or placebo (n = 41). Random assignment was done by using the random numbers generated by computer and a trained personnel at the endocrine clinic performed randomization. VSL#3 is a freeze-dried pharmaceutical probiotic preparation containing 112.5 × 109 CFU/capsule of eight strains of lactic acid bacteria (Streptococcus thermophilus, Bifidobacterium breve, Bifidobacterium longum, Bifidobacterium infantis, Lactobacillus acidophilus, Lactobacillus plantarum, Lactobacillus paracasei, and Lactobacillus delbrueckii subsp. Bulgaricus), microcrystalline cellulose, stearic acid, magnesium stearate, and vegetable capsule (hydroxypropyl methylcellulose), silicon dioxide. Some dairy ingredients are used in the culture medium but are removed during manufacturing. Identical-looking placebo capsules containing 40 mg microcrystalline cellulose were used for blinding. The capsules were stored at 2 to 8°C prior to distribution and the subjects were instructed to refrigerate the capsules.

GDM diagnosis will be based on the following criteria: 2 h, 75 g OGTT: fasting venous plasma glucose level, 5.5 mmol⋅L⁻¹ or higher or 75-g oral glucose tolerance test (OGTT) 2-hour venous plasma glucose level, 8.0 mmol⋅L⁻¹ or higher [20]. Exclusion criteria were an unwillingness to follow a prescribed diet, pre-GDM (either type 1 or type 2 DM), the need for insulin treatment, and pregnancy comorbidities other than obesity, hypertension, and/or dyslipidemia.

The study was approved by and performed under the guidelines of the Research Ethics Committee of Mazandaran University of Medical Sciences, Iran, and a written consent was obtained from all subjects.

The allocation of the intervention or control group was concealed from the researchers and the probiotic and placebo boxes had an identical appearance. Neither the subjects nor the investigators were aware of the treatment assignments in this double-blinded study. Ten days before the beginning of the trial, all patients refrained from eating yogurt or any other fermented foods or supplements. Over 8 wk, the intervention and placebo groups consumed probiotic and placebo capsules twice a day, respectively. All patients were asked, throughout the 8-week trial, to maintain their usual dietary habits and lifestyle and to avoid consuming any bacteria supplement other than that provided to them by the researchers and any fermented foods.

Arrangements were made so that the patients would receive a 2-week supply of their probiotic or placebo capsules every two weeks. Compliance with the consumption guidelines was monitored by telephone interviews once a week. Information on food consumption, anthropometric measurements, and fasting blood samples were collected at the beginning and at the end of the trial. Nutrient intakes during 3 d were estimated using a 24-hour dietary recall at the beginning and at the end of the study. Three-day averages of macronutrient and micronutrient intakes were analyzed by Nutritionist 4 software (First Databank, Hearst Corp, San Bruno, CA, USA).

Anthropometric measurements were recorded by trained personnel. Body weights were measured using a scale (Seca, Hamburg, Germany) with 0.1 kg accuracy without shoes and with minimum clothing. Heights were measured using a stadiometer (Seca) with 0.1 cm accuracy without shoes.
BMI was calculated by dividing body weight (kilograms) by height (meters) squared. Blood samples were collected from the antecubital vein while fasting (12-hour overnight fast) to determine baseline glucose and insulin and then repeated after 8 weeks of treatment. The serum samples were separated from whole blood by centrifugation at 3500 rpm for 10 min (Avanti J-25, Beckman, Brea, CA, USA). The serum and whole blood samples were frozen immediately at −70°C until the assay. Fasting blood glucose was measured using the standard enzymatic method with a Parsazmun kit (Karaj, Iran). Glycated hemoglobin (HbA1c) was measured in the whole blood by cation exchange chromatography with a NycoCard HbA1c kit (Oslo, Norway). Insulin concentration was determined by a chemiluminescent immunoassay using a Liaison analyzer (DiaSorin, Saluggia, Italy). Insulin resistance was assessed using the homeostatic model assessment of insulin resistance (HOMA-IR) formula. Inflammatory parameters containing high-sensitivity C-reactive protein (hs-CRP) and interleukin-6 (IL-6) were determined by the ELISA technique using commercially available kits (Quantikine Human, R&D Systems, Minneapolis, MN) and Interferon gamma (IFN-γ), tumor necrosis factor-α (TNF-α), and interleukin-10 (IL-10) levels were measured with an enzyme-linked immunosorbent assay kit (eBioscience, San Diego, California) in accordance with the manufacturers’ instructions.

The present study was conducted according to the guidelines laid down in the declaration of Helsinki and the protocol has been approved by the local ethics committee. The steering committee was established to monitor the trial.

SPSS version 17.0 (SPSS Inc., Chicago, IL, USA) computer software was used for the statistical analysis. The variables were expressed as means SD. After testing data for normality, Student’s t-test and paired Student’s t-test were used to compare values between baseline and the end of the study. P < 0.05 was considered significant for all the data analyzed.

3. Results

There were two women in the study group and five in the control group who required insulin treatment because glycaemic goals [21] were not reached with diet alone; these individuals were excluded from the study. Furthermore, two women in the study group and one woman in the control group were excluded because they delivered prematurely before 35 weeks of gestation. Participants did not report any adverse effects or symptoms.

The final data analyses included 37 women treated with probiotic capsule and 35 treated with placebo (Figure 1). The baseline characteristics (age, height, BMI, prepregnancy weight, weight at baseline and end of trial, and oral glucose tolerance test values containing 1h-2h and 3 h fasting glucose) of the 72 evaluable patients in the two groups were similar and there were no significant differences in the intention to treat baseline characteristics between the two groups, as shown in Table 1. The dietary intake of macronutrients among participants which is shown in Table 2 indicated that there were no significant differences in energy or macronutrient intake. In the other hands, Participants dietary composition did not significantly change during the study period (P > 0.05).

With intention to treat analysis and after 8 wk of supplementation FPG, HbA1c, HOMA-IR, and insulin levels remained unchanged in the probiotic and placebo group (P > 0.05). The comparison between the two groups showed that there were no significant differences with some glycemic parameters containing FPG and HbA1c (P > 0.05), but there were significant differences in insulin levels and HOMA-IR which were calculated based on the power of 80% and α = 5% (16.6 ± 5.9; 3.7 ± 1.5, resp.) (Table 3).

There was a significant decrease in levels of IL-6 (3.81 ± 0.7), TNF-α (3.10 ± 1.1), and hs-CRP (4927.4 ± 924.6). Reductions in levels of IFN-γ (19.21 ± 16.6) were not significant.

No significant increase was observed in IL-10 (3.11 ± 5.7) in the intervention group as compared with the control group after 8 wk (P > 0.05) (Table 3).

4. Discussion

There are some data from studies, mostly animal studies, which suggest mechanisms whereby probiotics may improve glycemic control, insulin resistance, and inflammatory status [22, 23].

To the best of our knowledge, no study has evaluated the impact of VSL#3 probiotics on inflammatory and glycemic status in patients with GDM. The present study suggests that supplementation with VSL#3 with different subspecies of *Lactobacillus*, *Bifidobacterium*, and *Streptococcus* may have a slight favorable effect on glycemic status. In the study, using the supplement product could not significantly affect FPG and HbA1c but prevented the rise in serum insulin concentration and increase in insulin resistance.

Several studies on the effects of different strains of probiotics on glycemic status in patients with GDM have yielded inconsistent results. One study in Finland was conducted to assess the efficacy of probiotic supplement in reducing the risk of GDM in pregnant women. In the study, 256 women were randomized in the first trimester of pregnancy to receive probiotic supplement (*Lactobacillus rhamnosus* ATCC 53103 and *Bifidobacterium lactis* Bb-12), while the control group received placebo. It has been concluded that the probiotic intervention has a positive effect of glycemic status because blood glucose concentrations were the lowest in the women receiving the probiotic intervention [24]. Our results with regard to prevention of increased serum insulin concentration and development of insulin resistance are similar to those of Asemi and colleagues [19], who showed that consumption of probiotic yogurt which was fermented with *Streptococcus thermophilus* and *Lactobacillus bulgaricus* and subsequently supplemented with *Bifidobacterium lactis* Bb-12 and *Lactobacillus acidophilus* LA5, for 9 weeks in the third trimester of pregnancy, prevented the increase in serum insulin levels and the development of insulin resistance. They showed that the probiotic yogurt could not significantly affect FPG, systolic and diastolic blood pressures compared with the conventional yogurt.
229 participated in screening visit

Assessed for eligibility ($n = 96$)

Excluded: 7 were ineligible, 7 did not want to participate

Randomized: 82

Allocated to probiotic group ($n = 41$)

Allocated to placebo group ($n = 41$)

Excluded: needed insulin treatment ($n = 2$); delivered prematurely before 35 weeks of gestation ($n = 2$)

Excluded: needed insulin treatment ($n = 5$); delivered prematurely before 35 weeks of gestation ($n = 1$)

Analyzed ($n = 37$)

Analyzed ($n = 35$)

**Figure 1:** Flow diagram of the study.

**Table 1:** Baseline characteristics of the intention-to-treat population.

| Variables                      | Probiotic group ($n = 41$) | Control group ($n = 41$) | $P$ value |
|--------------------------------|---------------------------|--------------------------|-----------|
| Age (year)                     | $32.4 \pm 3.1$            | $31.9 \pm 4.0$           | 0.20      |
| Height (cm)                    | $162.1 \pm 4.8$           | $160.9 \pm 4.6$          | 0.27      |
| BMI (kg/m$^2$)                 | $26.8 \pm 2.7$            | $27.4 \pm 3.1$           | 0.39      |
| Oral glucose tolerance test values (mmol/L) |                     |                          |   |
| Fasting glucose                | $5.2 \pm 0.6$             | $4.9 \pm 0.7$            | 0.34      |
| 1-hour glucose                 | $11.8 \pm 1.3$            | $11.1 \pm 1.6$           | 0.33      |
| 2-hour glucose                 | $10.4 \pm 1.2$            | $10.2 \pm 1.4$           | 0.39      |
| 3-hour glucose                 | $7.8 \pm 1.8$             | $7.6 \pm 1.6$            | 0.46      |
| Prepregnancy weight (kg)       | $70.4 \pm 7.3$            | $69.8 \pm 9.2$           | 0.37      |
| Weight at study baseline (kg)  | $72.9 \pm 6.6$            | $73.3 \pm 8.6$           | 0.47      |
| Parity $\geq 1$ (N)            | 16                        | 15                       | 0.64      |
| Gestational age (weeks)        | $26.4$                    | $26.6$                   | 0.49      |
| Weight at end of trial (kg)    | $74.9 \pm 7.7$            | $75.3 \pm 8.3$           | 0.34      |

BMI, body mass index; data are the means ± SD; obtained from an independent $t$-test.
Table 2: Dietary intakes of the intention-to-treat participants at baseline and at the end of the study.

| Variables                  | Period   | Probiotic group (n = 41) | Control group (n = 41) | P value* |
|----------------------------|----------|--------------------------|------------------------|----------|
| Energy (kcal/d)            | Initial  | 2331 ± 132               | 2382 ± 149             | 0.22     |
|                           | End      | 2288 ± 117               | 2310 ± 169             | 0.13     |
| Carbohydrate (g/d)        | Initial  | 310.8 ± 38.8             | 318.1 ± 39.1           | 0.23     |
|                           | End      | 302.4 ± 38.2             | 309.4 ± 39.8           | 0.29     |
| Protein (g/d)             | Initial  | 79.3 ± 11.4              | 80.4 ± 13.4            | 0.22     |
|                           | End      | 76.2 ± 14.2              | 78.7 ± 13.9            | 0.19     |
| Total fat (g/d)           | Initial  | 77.2 ± 12.6              | 79.6 ± 8.1             | 0.34     |
|                           | End      | 73.3 ± 13.2              | 74.1 ± 10.8            | 0.41     |
| Dietary fiber (g/d)       | Initial  | 13.8 ± 3.2               | 14.6 ± 3.8             | 0.25     |
|                           | End      | 13.1 ± 4.4               | 13.6 ± 3.9             | 0.29     |
| PUFA (g/d)                | Initial  | 20.9 ± 4.5               | 21.8 ± 3.9             | 0.36     |
|                           | End      | 25.1 ± 5.7               | 23.7 ± 6.1             | 0.19     |
| MUFA (g/d)                | Initial  | 21.9 ± 6.2               | 23.8 ± 5.8             | 0.48     |
|                           | End      | 19.8 ± 8.8               | 20.7 ± 6.2             | 0.56     |
| Zinc (mg/d)               | Initial  | 11.8 ± 3.1               | 9.8 ± 2.1              | 0.32     |
|                           | End      | 10.8 ± 2.6               | 10.4 ± 3.2             | 0.47     |
| Copper (mg/d)             | Initial  | 1.39 ± 0.3               | 1.42 ± 0.5             | 0.29     |
|                           | End      | 1.49 ± 0.5               | 1.55 ± 0.7             | 0.31     |

Table 3: Characteristics of patients who received probiotic or placebo, at baseline and after 8 weeks from diagnostic oral glucose tolerance test (OGTT).

|                        | First week | Eighth week | Change | First week | Eighth week | Change | P value |
|------------------------|------------|-------------|--------|------------|-------------|--------|---------|
| Weight in pregnancy (kg)| 73.2 ± 7.8 | 75.7 ± 8.3  | 2.5 ± 0.3 | 73.5 ± 9.6 | 76.2 ± 9.8  | 2.7 ± 0.4 | 0.21    |
| FPG (mg/dL)            | 91.6 ± 4.3 | 89.3 ± 3.4  | −2.3 ± 4.1 | 93.7 ± 3.1 | 88.9 ± 4.4  | −4.8 ± 3.6 | 0.42    |
| Insulin (μIU/mL)       | 19.1 ± 4.2 | 16.6 ± 5.9* | −2.5 ± 5.1 | 18.7 ± 5.8 | 22.3 ± 4.9  | 3.6 ± 5.5  | 0.04    |
| HOMA-IR                | 4.3 ± 1.2  | 3.7 ± 1.5*  | −0.6 ± 1.4 | 4.4 ± 1.3  | 4.9 ± 1.2   | 0.5 ± 1.2  | 0.03    |
| HbA1c (%)              | 4.8 ± 0.6  | 4.7 ± 0.5   | −0.1 ± 0.2 | 4.6 ± 0.1  | 4.6 ± 0.3   | 0.08 ± 0.2 | 0.44    |
| hs-CRP (ng/mL)         | 5723.4 ± 1832.0 | 4927.4 ± 924.6* | −796.0 ± 1087.2 | 5021.2 ± 1301.1 | 5996.5 ± 1118.8 | 975.3 ± 1121.2 | 0.03 |
| IL-10 (pg/mL)          | 2.37 ± 4.6 | 3.11 ± 5.7  | 0.74 ± 4.4 | 3.78 ± 6.3 | 3.38 ± 5.8  | −0.4 ± 5.1 | 0.54    |
| IFN-c                  | 16.84 ± 14.9 | 19.21 ± 16.6   | 2.37 ± 14.2 | 18.34 ± 13.4 | 21.11 ± 15.8 | 2.77 ± 11.8 | 0.67    |
| IL-6 (pg/mL)           | 4.25 ± 0.9  | 3.81 ± 0.7*  | −0.44 ± 0.5 | 4.38 ± 0.64 | 4.71 ± 0.53 | 0.33 ± 0.42 | 0.04    |
| TNF-α (pg/mL)          | 3.72 ± 1.0  | 3.10 ± 1.1*  | −0.62 ± 1.0 | 3.62 ± 1.2  | 4.07 ± 0.9  | 0.45 ± 0.8  | 0.04    |

All continuous variables are expressed as mean ± SD.

* Statistical significance (P < 0.05), obtained from independent samples t-test, indicates between group differences. HOMA-IR, homeostasis model assessment of insulin resistance. FPG, fasting plasma glucose. HbA1c, glycated Hb.

In another study, the rate of GDM was significantly reduced to 13% in women receiving specific probiotics. The results during the last trimester of pregnancy confirmed that blood glucose concentrations were statistically significantly the lowest in the probiotics group; better glycemic status in intervention group was confirmed by the low insulin concentration and homeostasis model assessment, in addition to the reduced risk of elevated glucose concentration compared with the placebo group. The researchers implied that benefits achieved by probiotic intervention were maybe the result of direct effect of modulation of host metabolism by probiotics and indirect effect of modified gut microbiota composition [25].

Lindsay et al. in a double-blind, placebo-controlled trial assessed the impact of a probiotic intervention in pregnant women with an early pregnancy body mass index from 30.0 to 39.9. The primary outcome was the change in fasting glucose between groups from preintervention to postintervention.
Secondary outcomes were the incidence of gestational diabetes and neonatal anthropometric measures. No differences in primary and secondary outcome were detected between the study groups, which is in agreement with our results in regard to the primary outcome [26].

In a recent study of 149 women with GDM, maternal fasting glucose decreased from preintervention to postintervention within both groups, but no difference in baseline-adjusted postintervention levels between intervention group with probiotic supplement subspieces *Lactobacillus salivarius* UCC118 and placebo group was detected [27]. The researchers described that the probiotic did not appear to have any beneficial glycemic effect or any improvement of pregnancy outcomes.

One of the common points of these studies was to describe exact mechanism involved in the protective effects of probiotics which is unclear. Inconsistent results of the effect of probiotics on glycemic status described above are maybe because of the strain-specificity of these microorganisms. Every strain of probiotic has its own specific and unique local and systemic immunomodulatory effects which is because of the specific conditions associated with altered gut barrier function [28, 29].

Another outcome of VSL#3 supplementation in patients with GDM was an improvement in inflammatory status. As the inflammatory signalling pathways involved are causally linked to insulin resistance [30], it is speculated that improvement of inflammatory status could be contributed to diabetes control [31]. Therefore, assessing the inflammatory status of patients may show the diabetes status indirectly. The results of the study provide insight into the anti-inflammatory effects of probiotic supplements in patients with gestational diabetes. Our results have shown that probiotic supplements significantly decreased IL-6, TNF-\(\alpha\), and hs-CRP in the intervention group as compared with the control group. The reductions in IFN-\(\gamma\) and the increase in IL-10 in the intervention group were not significant.

The results were in close agreement with the results as assessed by Matsuzaki et al. showing that *Lactobacillus casei* significantly decreased plasma levels of glucose and proinflammatory cytokines (such as IL-2 and IFN-\(\gamma\)) in none-insulin-dependent diabetic mice after 16 weeks [32].

The results are in line with some other studies; Mazloom et al. showed that interleukin-6 (IL-6) was reduced while CRP levels were elevated but the change was not statistically significant. Tvetman et al. showed that chewing gums (with two strains: *Lactobacillus reuteri* ATCC 55730 and ATCC PTA 5289) significantly reduced TNF-\(\alpha\) level [33], although this did not have any significant effect on IL-6 level in healthy adults [34]. Mohamadshahi et al. also reported a significant decrease of serum levels of TNF-\(\alpha\) by using a probiotic yogurt enriched with *Bifidobacterium animalis* subsp. Lactis Bb12 (DSM 10140) and *Lactobacillus acidophilus* strain La5 [35]. Asemi et al. in two separate studies with two different interventions (probiotic and symbiotic) in patients with type 2 diabetes reported that consumption of the probiotic yogurt appeared to attenuate low-grade inflammation by a significant decrease in sensitive CRP levels in pregnant women [19, 36]. All of the above studies have suggested that using of different species of probiotics may lead to inhibition of production of various proinflammatory cytokines.

However, there are some studies with inconsistent results in contrast with our study. Hatakka et al. considered a nonsignificant change of IL-6 and TNF-\(\alpha\) level in rheumatoid arthritis patients who take capsules of *Lactobacillus rhamnosus* LC70536. They showed that serum IL-1 beta increased slightly in the LGG group, but no differences were seen in IL-6, TNF-alpha, MPO, IL-10, or IL-12 [37]. Asemi et al. showed that the intake of probiotic yogurt for 9 weeks brought about a decrease in the serum hs-CRP level but did not decrease TNF-\(\alpha\) concentration [38].

The mechanism by which probiotic intake results in altered inflammatory and glycemic status is the gut microbiota. There are several studies which examined gut microbiota composition in diabetes or obesity on microbial flora [39–42]. Recent studies have shown that the association between gut bacteria can influence inflammatory state of patients through the component of the Gram-negative bacterial cell walls, which is called polysaccharide (LPS). This factor can trigger the inflammatory process by binding to the CD14 toll-like receptor-4 (TLR-4) complex. It is confirmed that deletion of TLR-4 can prevent the high-fat diet-induced insulin resistance [43].

Lee et al. considered a decline in TNF-\(\alpha\) concentration by *Lactobacillus* HY and they declared that it may be because of the inhibition of trinitrobenzene sulfonic acid and consequently inhibition of TNF-\(\alpha\) gene expression [44]. Another mechanism for anti-inflammatory effect of probiotics is through NF-\(\kappa\)B signalling pathway. In a study, *Bifidobacterium longum* decreased TNF-\(\alpha\) concentration by suppressing NF-\(\kappa\)B activation of lamina propria mononuclear cells which will lead to downregulation of TNF-\(\alpha\) production [45]. Therefore, the mechanism of probiotics in GDM could be summarized as altering the properties and profile of gut microbiota to a balanced situation which will lead to an improvement of intestinal permeability function and to a regulated concentration of proinflammatory mediators. However, because of the diversity of human gut microbiota and because of the strain-specificity and multifunctionality of various species of probiotic, it is essential to clarify the complex mechanisms of action that contribute to the effects of probiotics intakes on secretion of proinflammatory mediators, which are only lately being unraveled.

Our study had some limitations. The duration of the intervention was 8 weeks and we were unable to administer the supplement for a longer period due to budget limitations. We were unable to measure fasting glucose and serum insulin levels repeatedly. We could not assess the pregnancy and neonatal outcome data. We did not assay other inflammatory or anti-inflammatory biomarkers. The small sample size for detecting the difference in the primary outcomes is another limitation. We also did not evaluate microbial composition of gut and feces.

5. Conclusions

According to the results of this trial, clear differences in glycemic status and especially inflammatory mediators...
are revealed in this study. But we cannot draw any firm conclusion about using probiotics in health improvement profile of GDM patients, clinically. Future studies and further randomized trials of probiotics on pregnancy outcomes are suggested to fully elucidate the potential effects of probiotics in GDM patients.

**Competing Interests**

The authors declare that they have no competing interests.

**References**

[1] P. Sreelakshmi, S. Nair, B. Soman, R. Alex, K. Vijayakumar, and V. Kuty, "Maternal and neonatal outcomes of gestational diabetes: a retrospective cohort study from Southern India," *Journal of Family Medicine and Primary Care*, vol. 4, no. 3, p. 395, 2015.

[2] D. B. Carr, K. M. Newton, K. M. Utschneider et al., "Gestational diabetes or lesser degrees of glucose intolerance and risk of preeclampsia," *Hypertension in Pregnancy*, vol. 30, no. 2, pp. 153–163, 2011.

[3] J. C. Dempsey, Z. Ashiny, C. -F. Qiu, R. S. Miller, T. K. Sorensen, and M. A. Williams, "Maternal pre-pregnancy overweight status and obesity as risk factors for cesarean delivery," *The Journal of Maternal-Fetal and Neonatal Medicine*, vol. 17, no. 3, pp. 179–185, 2005.

[4] M. D. Nitert, H. L. Barrett, K. Foxcroft et al., "SPRING: an RCT study of probiotics in the prevention of gestational diabetes mellitus in overweight and obese women," *BMC Pregnancy and Childbirth*, vol. 13, article 50, 2013.

[5] E. M. Wendland, M. R. Torloni, M. Falavigna et al., "Gestational diabetes and pregnancy outcomes—a systematic review of the World Health Organization (WHO) and the International Association of Diabetes in Pregnancy Study Groups (IADPSG) diagnostic criteria," *BMC Pregnancy and Childbirth*, vol. 12, article 23, 2012.

[6] L. L. Lipscombe, A. T. Banerjee, S. McTavish et al., "Readiness for diabetes prevention and barriers to lifestyle change in women with a history of gestational diabetes mellitus: rationale and study design," *Diabetes Research and Clinical Practice*, vol. 106, no. 1, pp. 57–66, 2014.

[7] S. P. Palem and P. Abraham, "A study on the level of oxidative stress and inflammatory markers in type 2 diabetes mellitus patients with different treatment modalities," *Journal of Clinical and Diagnostic Research*, vol. 9, no. 9, pp. BC04–BC07, 2015.

[8] M. Blaser, "Antibiotic overuse: stop the killing of beneficial bacteria," *Nature*, vol. 476, no. 7361, pp. 393–394, 2011.

[9] G. D. Wu, J. Chen, C. Hoffmann et al., "Linking long-term dietary patterns with gut microbial enterotypes," *Science*, vol. 334, no. 6052, pp. 105–108, 2011.

[10] R. E. Ley, P. J. Turnbaugh, S. Klein, and J. I. Gordon, "Microbial ecology: human gut microbes associated with obesity," *Nature*, vol. 444, no. 7122, pp. 1022–1023, 2006.

[11] M. G. Redman, E. J. Ward, and R. S. Phillips, "The efficacy and safety of probiotics in people with cancer: a systematic review," *Annals of Oncology*, vol. 25, no. 10, pp. 1919–1929, 2014.

[12] G. Reid, J. Jass, M. T. Sebulsky, and J. K. McCormick, "Potential uses of probiotics in clinical practice," *Clinical Microbiology Reviews*, vol. 16, no. 4, pp. 658–672, 2003.

[13] P. Gionchetti, F. Rizzello, A. Venturi et al., "Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial," *Gastroenterology*, vol. 119, no. 2, pp. 305–309, 2000.

[14] R. K. Dhiman, B. Rana, S. Agrawal et al., "Probiotic VSL.#3 reduces liver disease severity and hospitalization in patients with cirrhosis: a randomized, controlled trial," *Gastroenterology*, vol. 147, no. 6, pp. 1327–1337.e3, 2014.

[15] R. N. Fedorak, B. G. Feagan, N. Hotte et al., "The probiotic vsl3# has anti-inflammatory effects and could reduce endoscopic recurrence after surgery for Crohn’s disease," *Clinical Gastroenterology and Hepatology*, vol. 13, no. 5, pp. 928–935.e2, 2015.

[16] P. Mastromarino, D. Capobianco, A. Micchelli et al., "Administration of a multistrain probiotic product (VSL#3) to women in the perinatal period differentially affects breast milk beneficial microbiota in relation to mode of delivery," *Pharmacological Research*, vol. 95–96, pp. 63–70, 2015.

[17] S. Rohatgi, V. Ahuja, G. K. Makharia et al., "VSL#3 induces and maintains short-term clinical response in patients with active microscopic colitis: a two-phase randomised clinical trial," *BMJ Open Gastroenterology*, vol. 2, no. 1, Article ID e000018, 2015.

[18] S. J. Allen, S. Jordan, M. Storey et al., "Dietary supplementation with lactobacilli and bifidobacteria is well tolerated and not associated with adverse events during late pregnancy and early infancy," *Journal of Nutrition*, vol. 140, no. 3, pp. 483–488, 2010.

[19] Z. Asemi, M. Samimi, Z. Tabassi et al., "Effect of daily consumption of probiotic yoghurt on insulin resistance in pregnant women: a randomized controlled trial," *European Journal of Clinical Nutrition*, vol. 67, no. 1, pp. 71–74, 2013.

[20] L. Hoffman, C. Nolan, J. D. Wilson, J. J. N. Oats, and D. Simmons, "Gestational diabetes mellitus—management guidelines. The Australasian diabetes in pregnancy society," *The Medical Journal of Australia*, vol. 169, no. 2, pp. 93–97, 1998.

[21] American Diabetes Association, "Diagnosis and classification of diabetes mellitus," *Diabetes Care*, vol. 33, supplement 1, pp. 562–569, 2009.

[22] M. Ljungberg, R. Korpela, J. Ilonen, J. Ludvigsson, and O. Vaarala, "Probiotics for the prevention of beta cell autoimmunity in children at genetic risk of type 1 diabetes—the PRODIA study," *Annals of the New York Academy of Sciences*, vol. 1079, pp. 360–364, 2006.

[23] T. Yamano, M. Tanida, A. Nijjima et al., "Effects of the probiotic strain Lactobacillus johnsonii strain La1 on autonomic nerves and blood glucose in rats," *Life Sciences*, vol. 79, no. 20, pp. 1963–1967, 2006.

[24] P. D. Cani, S. Possemiers, T. Van de Wiele et al., "Changes in gut microbiota control inflammation in obese mice through a mechanism involving GLP-2-driven improvement of gut permeability," *Gut*, vol. 58, no. 8, pp. 1091–1103, 2009.

[25] J. Ilonen, E. Isolauri, T. Poussa, and K. Laitinen, "Impact of dietary counselling and probiotic intervention on maternal anthropometric measurements during and after pregnancy: a randomized placebo-controlled trial," *Clinical Nutrition*, vol. 30, no. 2, pp. 156–164, 2011.

[26] K. L. Lindsay, M. Kennelly, M. Culliton et al., "Probiotics in obese pregnancy do not reduce maternal fasting glucose: a double-blind, placebo-controlled, randomized trial (Probiotics in Pregnancy Study)," *The American Journal of Clinical Nutrition*, vol. 99, no. 6, pp. 1432–1439, 2014.

[27] K. L. Lindsay, L. Brennan, M. A. Kennelly et al., "Impact of probiotics in women with gestational diabetes mellitus on
metabolic health: a randomized controlled trial,” *American Journal of Obstetrics and Gynecology*, vol. 212, no. 4, pp. 496.e1–496.e11, 2015.

[28] J. K. Collins, C. Dunne, L. Murphy et al., “A randomised controlled trial of a probiotic *Lactobacillus* strain in healthy adults: assessment of its delivery, transit and influence on microbial flora and enteric immunity,” *Microbial Ecology in Health and Disease*, vol. 14, no. 2, pp. 81–89, 2002.

[29] S. Tachon, B. Lee, and M. L. Marco, “Diet alters probiotic *Lactobacillus* persistence and function in the intestine,” *Environmental Microbiology*, vol. 16, no. 9, pp. 2915–2926, 2014.

[30] E. S. Yeo, J. Y. Hwang, J. E. Park, Y. J. Choi, K. B. Huh, and W. Y. Kim, “Tumor necrosis factor (TNF-α) and c-reactive protein (CRP) are positively associated with the risk of chronic kidney disease in patients with type 2 diabetes,” *Yonsei Medical Journal*, vol. 51, no. 4, pp. 519–525, 2010.

[31] B. Garcia-Bailo, A. El-Sohemy, P. S. Haddad et al., “Vitamins D, C, and E in the prevention of type 2 diabetes mellitus: modulation of inflammation and oxidative stress,” *Bioscience, Targets & Therapy*, vol. 5, pp. 7–19, 2011.

[32] T. Matsuzaki, R. Yamazaki, S. Hashimoto, and T. Yokokura, “Antidiabetic effects of an oral administration of *Lactobacillus casei* in a non-insulin-dependent diabetes mellitus (NIDDM) model using KK-A(y) mice,” *Endocrine Journal*, vol. 44, no. 3, pp. 357–365, 1997.

[33] S. Twetman, B. Derawi, M. Keller, K. Ekstrand, T. Yucel-Lindholm, and C. Stecksén-Blicks, “Short-term effect of chewing gums containing probiotic *Lactobacillus reuteri* on the levels of inflammatory mediators in gingival crevicular fluid,” *Acta Odontologica Scandinavica*, vol. 67, no. 1, pp. 19–24, 2009.

[34] Z. Mazloom, A. Yousefinejad, and M. H. Dabaghmanesh, “Effect of probiotics on lipid profile, glycemic control, insulin action, oxidative stress, and inflammatory markers in patients with type 2 diabetes: a clinical trial,” *Iranian Journal of Medical Sciences*, vol. 38, no. 1, pp. 38–43, 2013.

[35] M. Mohamadshahi, M. Veissi, F. Haidari, H. Shahbazian, G.-A. Kaydani, and F. Mohammadi, “Effects of probiotic yoghurt consumption on inflammatory biomarkers in patients with type 2 diabetes,” *Biological Impacts*, vol. 4, no. 2, pp. 83–88, 2014.

[36] Z. Asemi, S. Jazayeri, M. Najafi et al., “Effect of daily consumption of probiotic yoghurt on oxidative stress in pregnant women: a randomized controlled clinical trial,” *Annals of Nutrition and Metabolism*, vol. 60, no. 1, pp. 62–68, 2012.

[37] K. Hatakka, J. Martio, M. Korpela et al., “Effects of probiotic therapy on the activity and activation of mild rheumatoid arthritis—a pilot study,” *Scandinavian Journal of Rheumatology*, vol. 32, no. 4, pp. 211–215, 2003.

[38] S. Asemi, S. Jazayeri, M. Najafi et al., “Effects of daily consumption of probiotic yoghurt on inflammatory factors in pregnant women: a randomized controlled clinical trial,” *Pakistan Journal of Biological Sciences*, vol. 14, no. 8, pp. 476–482, 2011.

[39] N. Larsen, F. K. Vogensen, F. W. J. van den Berg et al., “Gut microbiota in human adults with type 2 diabetes differs from non-diabetic adults,” *PLoS ONE*, vol. 5, no. 2, Article ID e9085, 2010.

[40] I. Nadal, A. Santacruz, A. Marcos et al., “Shifts in clostridia, bacteroides and immunoglobulin-coating fecal bacteria associated with weight loss in obese adolescents,” *International Journal of Obesity*, vol. 33, no. 7, pp. 758–767, 2009.

[41] A. Santacruz, A. Marcos, J. Wärnberg et al., “Interplay between weight loss and gut microbiota composition in overweight adolescents,” *Obesity*, vol. 17, no. 10, pp. 1906–1915, 2009.

[42] X. Wu, C. Ma, L. Han et al., “Molecular characterisation of the faecal microbiota in patients with type II diabetes,” *Current Microbiology*, vol. 61, no. 1, pp. 69–78, 2010.

[43] H. Shi, M. V. Kokoeva, K. Inouye, I. Tzameli, H. Yin, and J. S. Flier, “TLR4 links innate immunity and fatty acid-induced insulin resistance,” *The Journal of Clinical Investigation*, vol. 116, no. II, pp. 3015–3025, 2006.

[44] J.-H. Lee, B. Lee, H.-S. Lee et al., “Lactobacillus sanfrancisco inhibits pro-inflammatory cytokine expression and TLR-4-linked NF-κB activation in experimental colitis,” *International Journal of Colorectal Disease*, vol. 24, no. 2, pp. 231–237, 2009.

[45] X.-Z. Shi, P. F. Lindholm, and S. K. Sarna, “NF-κB activation by oxidative stress and inflammation suppresses contractility in colonic circular smooth muscle cells,” *Gastroenterology*, vol. 124, no. 5, pp. 1369–1380, 2003.